Novartis has agreed to acquire UK-based biotechnology company Myricx Bio in a deal valued at $1.1 billion upfront, with up to $400 million in additional milestone payments, to expand its antibody-drug conjugate (ADC) portfolio.
Myricx is developing ADCs that incorporate N-myristoyltransferase inhibitor (NMTi) payloads, a novel mechanism designed to disrupt protein function essential for cancer cell survival. The approach is intended to address limitations associated with commonly used ADC payload classes, including resistance observed with topoisomerase-1 inhibitors.
The acquisition will add two lead programs targeting B7-H3 and HER2, both of which are being explored across multiple solid tumor indications. Novartis said the deal will strengthen its oncology pipeline and broaden its capabilities in targeted therapies.
ADCs combine monoclonal antibodies with cytotoxic payloads to selectively deliver treatment to tumor cells. While the modality has gained traction in oncology, developers continue to seek new payload technologies to improve efficacy and overcome resistance mechanisms.
Preclinical data from Myricx suggest its NMTi-based payload platform may have activity in a range of solid tumors, including models resistant to existing ADC payloads. The technology could potentially be applied across multiple targets if validated in clinical studies.
The transaction is expected to close in the second half of 2026, subject to customary regulatory approvals and closing conditions.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!